Physician profile
Uzma Malik
NPI 1952362527
$3,824.07
in general payments reported to CMS, 2019-2025
54 companies · $961 in 2025
The $961 reported for 2025 was more than what 83% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $184 · 2020: $335 · 2021: $584 · 2022: $213 · 2023: $432 · 2024: $1,116 · 2025: $961.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,508.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,508.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $570.42 | 2023-2025 | Provenge |
| Novartis Pharmaceuticals Corporation | $354.61 | 2019-2025 | |
| Janssen Biotech, INC. | $295.95 | 2023-2024 | Rybrevant, Erleada |
| Tempus Ai, INC | $182.60 | 2024-2025 | Xt Cdx |
| Bayer Healthcare Pharmaceuticals INC. | $167.54 | 2020-2024 | |
| Daiichi Sankyo INC. | $139.57 | 2019-2024 | Enhertu |
| Tersera Therapeutics LLC | $138.26 | 2023-2025 | Zoladex, Xermelo |
| Merck Sharp & Dohme LLC | $138.25 | 2019-2023 | Keytruda, Lynparza |
| Pfizer INC. | $135.28 | 2020-2025 | |
| Beigene USA, INC. | $122.99 | 2024 | Brukinsa |
| Lilly USA, LLC | $98.26 | 2020-2025 | Jaypirca, Verzenio, Retevmo |
| Ipsen Biopharmaceuticals, INC | $94.85 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $90.93 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.64 | 2021 | |
| Genzyme Corporation | $83.97 | 2021-2025 |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Uzma Malik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.